BioSpace News Archive

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON) announced today that it will report its second quarter 2023 financial and operating results after the close of U.S. financial markets on Monday, August 14, 2023.

KALA BIO, Inc. announced that management will participate in the following investor conferences in August 2023:

Capricor Therapeutics will release its financial results for the second quarter ended June 30, 2023, after the market close on Monday, August 7, 2023.

Xenon Pharmaceuticals Inc. announced it will report its second quarter 2023 financial and operating results after the close of U.S. financial markets on Wednesday, August 9, 2023.

Adaptive Biotechnologies Corporation reported financial results for the quarter ended June 30, 2023.

Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, provided a corporate update and reported financial results for the quarter ended June 30, 2023.

Genelux Corporation announced that Thomas Zindrick, President, CEO and Chairman, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at BTIG’s Virtual Biotechnology Conference 2023.

Aravive, Inc. (Nasdaq: ARAV, “the Company”) today announced that its Phase 3 AXLerate-OC trial evaluating the safety and efficacy of batiraxcept in platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in the pre-specified subset of patients naïve to prior bevacizumab treatment.

Journey Medical Corporation announced the Company will release its second quarter 2023 financial results after the U.S. financial markets close on Tuesday, August 8, 2023.

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today reported financial results for the quarter ended June 30, 2023, and recent business highlights.